Keyphrases
Alopecia
100%
Targeted Cancer Therapy
100%
Confidence Interval
71%
Relative Risk
28%
Meta-analysis
14%
Mammalian Target of Rapamycin (mTOR)
14%
Placebo
14%
Vismodegib
14%
Bruton's Tyrosine Kinase
14%
Chemotherapy
14%
Extracellular Signal-regulated Kinase
14%
Vascular Endothelial Growth Factor
14%
Platelet-derived Growth Factor Receptor (PDGFR)
14%
Fixed Effects Model
14%
Random Effects Model
14%
PubMed
14%
Clinical Reports
14%
Fibrosarcoma
14%
Oncogenic Pathways
14%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Targeted Therapy
14%
Epidermal Growth Factor Receptor
14%
Meeting Abstracts
14%
Bortezomib
14%
Web of Science
14%
ERK MAPK
14%
CD30
14%
CD20
14%
Vascular Endothelial Growth Factor Receptor (VEGFR)
14%
Janus Kinase
14%
Anaplastic Lymphoma Kinase
14%
Dermatological Adverse Effects
14%
Medicine and Dentistry
Alopecia Mucinosa
100%
Cancer Treatment
100%
Platelet Derived Growth Factor Receptor
28%
Clinical Trial
14%
Meta-Analysis
14%
Placebo
14%
Adverse Event
14%
Vismodegib
14%
Phosphotransferase
14%
Fibrosarcoma
14%
Mitogen-Activated Protein Kinase
14%
Epidermal Growth Factor Receptor
14%
Targeted Therapy
14%
Epidermal Growth Factor Receptor 2
14%
Proteasome
14%
Gamma Urogastrone
14%
Vasculotropin
14%
Mechanistic Target of Rapamycin
14%
Bortezomib
14%
Dermatological Agent
14%
Random Effects Model
14%
CD20
14%
Janus Kinase
14%
CTLA-4
14%
Vasculotropin Receptor
14%
Anaplastic Lymphoma Kinase
14%
Bruton Tyrosine Kinase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Alopecia
100%
Platelet Derived Growth Factor Receptor
28%
Clinical Trial
14%
Phosphotransferase
14%
Mammalian Target of Rapamycin
14%
Vismodegib
14%
Adverse Event
14%
Placebo
14%
Chemotherapy
14%
Vasculotropin
14%
Epidermal Growth Factor Receptor
14%
Fibrosarcoma
14%
Proteasome
14%
Epidermal Growth Factor Receptor 2
14%
Gamma Urogastrone
14%
Janus Kinase
14%
Random Effects Model
14%
Bortezomib
14%
Dermatological Agent
14%
Vasculotropin Receptor
14%
Bruton Tyrosine Kinase
14%
Anaplastic Lymphoma Kinase
14%
Cytotoxic T Lymphocyte Antigen 4
14%